Clinical Trial Update: A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

View source ↗

Summary

This completed study evaluates the immune response to COVID-19 vaccination in patients with multiple sclerosis treated with ofatumumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Status: COMPLETED